May 25, 2017 1:28 AM ET

Life Sciences Tools and Services

Company Overview of Synexus Limited

Company Overview

Synexus Limited engages in the identification, recruitment, and retention of patients for clinical trials on behalf of sponsors that include pharmaceutical companies, biotechnology companies, and contract research organizations. The company offers feasibility, consultancy, project management, and medical imaging services. It provides services in various therapeutic areas, such as cardiovascular, neurology and psychiatry, endocrinology and metabolism, musculoskeletal, respiratory, dermatology, gastroenterology, infectious disease, ophthalmology, urology, women’s health, screenable medical conditions, and other areas; and ear, nose, and throat areas. The company was founded in 1998 and is head...

First floor, Williams House

Manchester Science Park

Lloyd Street North

Manchester,  M15 6SX

United Kingdom

Founded in 1998

155 Employees


44 1616 087 790


44 1616 087 797

Key Executives for Synexus Limited

Chief Executive Officer and Director
Age: 54
Chief Financial Officer and Director
Chief Operating Officer
Chief Medical Officer
Managing Director of Central and Eastern Europe
Compensation as of Fiscal Year 2016.

Synexus Limited Key Developments

Synexus Opens New Dedicated Clinical Research Site in Frankfurt, Germany; to Lead New Facility by Nicole Freibott

Synexus announced the opening of a new Dedicated Clinical Research Site in Frankfurt. The expansion into new facilities in Frankfurt supports the global company mission to be the patient’s choice for clinical research and to offer customers efficiency in the clinical trial process by recruiting more engaged patients from more capable sites. At the formal opening of the new Synexus Frankfurt Clinical Research Site, Dr. Christophe Berthoux, CEO of Synexus, was joined by Christoph Dietrich, the Managing Director of Synexus Germany and by Nicole Freibott, Head of the Synexus Frankfurt Clinical Research Site. Representatives of pharma, CRO, partner GPs and specialists were present to celebrate this important occasion and to reiterate the company’s long term plans to build service capability in this country where pharmaceutical and biotech companies are continuing to conduct a large number of clinical trials. The new clinic, which will be managed by Nicole Freibott, is placed ideally for easy patient access as it is located in the inner city, close to the popular shopping street Zeil with immediate access to public transport and parking facilities.

Synexus Seeks Acquisitions

Synexus Limited is looking for acquisition. Synexus intends to become a major player in the US, continue to expand its existing network of sites in Europe and Africa and develop a presence in Asia and South America.

Synexus Announces Board Appointments

Following the completion of the management buyout of Synexus the new board confirms its intention to expand the company's footprint through organic growth and acquisition. The new board members of Synexus are: Chairman Charles Woler and non-executives Benjamin Harrild, Hywel Evans, Ged Gould and Simon Braham. CEO of Synexus, Christophe Berthoux, and Financial Director of Synexus, Paul Chambers, will remain on the board. Chairman Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies, SMEs and lately in smaller, earlier stage companies - positions included Chairman and CEO of Roche France, Chairman of SmithKline Beecham's European pharmaceutical business, and CEO of Cadus Pharmaceuticals. Benjamin Harrild is the head of UK for the direct lending team of BlueBay Asset Management LLP, and was part of BlueBay's direct lending business from its inception in 2011. Hywel Evans has a wide experience in pharma and the CRO sector. His experience includes being Managing Director of Novo Nordisk UK, Managing Director of Takeda Pharmaceuticals UK, and after joining Quintiles he rose to become President of Europe. He is also Chairman of Western Sussex Hospitals NHS Trust. Ged Gould is Director and Office Head of LDC Manchester - part of the Lloyds Group - and has over 20 years of experience from the advisory arena, private equity, as well as being the Finance Director of two private equity backed businesses. Simon Braham is the Investment Director at LDC Manchester and has over 17 years' experience in advisory, banking, restructuring and private equity.

Similar Private Companies By Industry

Company Name Region
14M Genomics Ltd Europe
AB-Polyblok Ltd Europe
Ablatus Therapeutics Limited Europe
Accuro Biologics Ltd. Europe
ActinoPharma Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Synexus Limited, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at